This article was originally published on this site
It has been a while since I have done a Biotech Mailbag columnGiven recent and significant news around a few small biotech names I have profiled in 2021, it seems a good time to circle back and update the investment thesis around these concernsLet’s start with Strongbridge Biopharma (SBBP) . The company agreed to merge with Xeris Pharmaceuticals (…
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a subscriber? Please Login